338 results on '"Grever, Michael R,"'
Search Results
2. Evaluation of bleeding events in patients receiving acalabrutinib therapy
3. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
4. Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
5. Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
6. Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy
7. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia
8. Clinical Development of 2′-Deoxycoformycin
9. Second cancer incidence in CLL patients receiving BTK inhibitors
10. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients
11. Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
12. Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
13. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
14. Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
15. Supplementary Tables 1-2 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
16. Supplementary table 2 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
17. supplemental legend from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
18. Supplementary Figure Legends from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
19. Supplementary Figures 1-7 from A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
20. Supplementary figure 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
21. Two-inhibitor salvage therapy for hairy cell leukemia
22. Historical overview of hairy cell leukemia
23. BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation
24. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
25. FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
26. Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
27. Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
28. Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
29. Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
30. Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
31. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib
32. Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
33. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy
34. Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.
35. Racial and socioeconomic disparities among patients with chronic lymphocytic leukemia: Analysis of Surveillance, Epidemiology, and End Results program data.
36. Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album
37. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
38. The Role of Plants in the Drug Discovery Program of the United States National Cancer Institute
39. Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib
40. Characterization of Cytotoxic Macrophages in a Pre-Clinical Model of Epstein-Barr Virus (EBV)-Driven Lymphoproliferative Disease
41. Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status
42. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
43. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
44. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
45. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
46. Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia
47. Counting Chromosome Abnormalities in Chronic Lymphocytic Leukemia: Comparison of Iscn 2020 and MDS International Working Group Guidelines for Establishing Karyotype Complexity
48. Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL
49. DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma
50. Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.